The success of nanotechnology depends upon the ability of the biological system to tolerate the nanomaterials without any adverse effects. The successful commercialization of these remarkable materials is impeded by a few obstacles, one of the major challenges being the immunological response to these materials. The other major impediments are the cost and large scale production. While the former requires further investigations on the short-term and long-term toxicity of nanomaterials along with suitable modifications to alleviate the same, the latter issue can be tackled with the development and design of smart production processes.

The Centre is currently engaged in evaluating the biocompatibility of nanomaterials to determine their applicability for biomedical applications.